Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/185037
Full metadata record
DC FieldValueLanguage
dc.contributor.authorClèries Soler, Ramon-
dc.contributor.authorBuxó, Maria-
dc.contributor.authorVilardell, Mireia-
dc.contributor.authorAmeijide, Alberto-
dc.contributor.authorMartínez, José Miguel-
dc.contributor.authorFont, Rebeca-
dc.contributor.authorMarcos Gragera, Rafael-
dc.contributor.authorPuigdemont, Montserrat-
dc.contributor.authorViñas, Gemma-
dc.contributor.authorCarulla, Marià-
dc.contributor.authorEspinàs Piñol, Josep Alfons-
dc.contributor.authorGalceran, Jaume-
dc.contributor.authorIzquierdo i Font, Àngel Xavier-
dc.contributor.authorBorràs, Josep Maria-
dc.date.accessioned2022-04-19T13:21:38Z-
dc.date.available2022-04-19T13:21:38Z-
dc.date.issued2022-03-18-
dc.identifier.issn1660-4601-
dc.identifier.urihttp://hdl.handle.net/2445/185037-
dc.description.abstractBreast cancer (BC) is globally the most frequent cancer in women. Adherence to endocrine therapy (ET) in hormone-receptor-positive BC patients is active and voluntary for the first five years after diagnosis. This study examines the impact of adherence to ET on 10-year excess mortality (EM) in patients diagnosed with Stages I to III BC (N = 2297). Since sample size is an issue for estimating age- and stage-specific survival indicators, we developed a method, ComSynSurData, for generating a large synthetic dataset (SynD) through probabilistic graphical modeling of the original cohort. We derived population-based survival indicators using a Bayesian relative survival model fitted to the SynD. Our modeling showed that hormone-receptor-positive BC patients diagnosed beyond 49 years of age at Stage I or beyond 59 years at Stage II do not have 10-year EM if they follow the prescribed ET regimen. This result calls for developing interventions to promote adherence to ET in patients with hormone receptor-positive BC and in turn improving cancer survival. The presented methodology here demonstrates the potential use of probabilistic graphical modeling for generating reliable synthetic datasets for validating population-based survival indicators when sample size is an issue.-
dc.format.extent17 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI AG-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijerph19063605-
dc.relation.ispartofInternational Journal of Environmental Research and Public Health, 2022, vol. 19, num. 6-
dc.relation.urihttps://doi.org/10.3390/ijerph19063605-
dc.rightscc by (c) Clèries Soler, Ramon et al, 2022-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationCàncer de mama-
dc.subject.classificationEndocrinologia-
dc.subject.otherBreast cancer-
dc.subject.otherEndocrinology-
dc.titleNo Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec723021-
dc.date.updated2022-04-19T10:50:49Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid35329292-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
ijerph-19-03605.pdf1.93 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons